Sara Weaver
Primary Care · Danville, VANPI 1669016044
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,271, 2.1 times the $601 reported in 2021. Among primary care clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$752
- AstraZeneca$579
- Amgen$410
- Novo Nordisk$378
- Johnson & Johnson$311
- Merck$244
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,54499%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $752 |
| AstraZeneca | 25 | $579 |
| Amgen | 25 | $410 |
| Novo Nordisk | 13 | $378 |
| Johnson & Johnson | 18 | $311 |
| Merck | 15 | $244 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $233 |
| Bayer | 8 | $149 |
| Boehringer Ingelheim | 9 | $146 |
| Bridgebio Pharma, Inc. | 5 | $144 |
| Pfizer | 8 | $127 |
| United Therapeutics Corporation | 6 | $126 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $106 |
| Esperion Therapeutics, Inc. | 5 | $88 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| Scpharmaceuticals Inc. | 4 | $75 |
| Actelion Pharmaceuticals US, Inc. | 3 | $71 |
| Lexicon Pharmaceuticals, Inc. | 3 | $66 |
| Philips North America LLC | 2 | $58 |
| Boston Scientific | 2 | $51 |
| Vifor Pharma, Inc. | 3 | $49 |
| GSK | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $39 |
| Inari Medical, Inc. | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $35 |
| Cvrx, Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Medicomp Inc | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,582 in reported general payments places this provider in the 95th percentile of 142 primary care providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 63 | $62,123 |
| XareltoRivaroxaban | 53 | $37,457 |
| EntrestoSacubitril/Valsartan | 32 | $31,259 |
| FarxigaDapagliflozin Propanediol | 23 | $18,536 |
| Amiodarone Hcl | 97 | $2,763 |
| Nebivolol Hcl | 41 | $2,027 |
| Metoprolol Succinate | 161 | $1,876 |
| Olmesartan Medoxomil | 97 | $1,495 |
| Carvedilol | 139 | $1,434 |
| Hydralazine Hcl | 117 | $1,410 |
| Nifedipine ErNifedipine | 34 | $886 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 12 | $835 |
| Losartan Potassium | 84 | $745 |
| Amlodipine Besylate | 190 | $622 |
| Warfarin Sodium | 58 | $574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $127 | $62,12363 claims |
| Johnson & JohnsonXarelto | $311 | $37,45753 claims |
| NovartisEntresto | $752 | $31,25932 claims |
| AstraZenecaFarxiga | $579 | $18,53623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 primary care providers in Virginia.
Other primary care in Danville
- Lisa LewisDanville$4K
- Ann Marie KnightDanville$1K
- Rebecca GrinsellRichmond$12K
- Jennifer CampbellNewport News$8K
- Tien MaAnnandale$7K
- Michael CogginAshland$7K
- Erin StewartFredericksburg$6K
- Lawanda WoodNorfolk$6K
- Luis Rivera PenaFalls Church$4K
- Erika RobinsonFredericksburg$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.